To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
67 Current news of Merck Sharp & Dohme
rss
European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn
Doctors should no longer prescribe these medicines and should review patients’ treatment options
23-01-2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed the recommendation to suspend the marketing authorisations of Tredaptive, Pelzont and Trevaclyn (nicotinic acid / laropiprant) used to treat adults with dyslipidaemia.The CHMP decision follows ...
Merck Animal Health Facility Among the First Sites Certified According to New Standard CWA 15793:2008 on Laboratory Biorisk Management
27-06-2012
The Merck Animal Health (known as MSD Animal Health outside the United States and Canada) foot-and-mouth disease (FMD) research and vaccine manufacturing site in Cologne (Germany) is among the first facilities worldwide that have been certified according to the new standard CWA 15793:2008 on ...
MSD/Merck: Centralized Animal Health Headquarter in New Jersey, US
02-02-2012
MSD Animal Health, known as Merck Animal Health in the United States and Canada, announced that it intends to centralize certain functions at the existing Merck Campus in Summit, New Jersey, USA.The plan, taken as part of the business’s worldwide strategic plan and blueprint for significant ...
Candidate vaccine against deadly pneumonia in foals
16-09-2011
Rhodococcus equi bacteria can cause “rattles”, a potentially lethal disease in foals which is characterized by pneumonia and gastro-intestinal infection. Despite the severity of this disease, a vaccine against it is not available yet. Researchers at the Groningen Biomolecular Sciences and ...
Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health
Former Becton Dickinson and Wyeth Executive Joins Merck
25-08-2011
Merck, known as MSD outside the United States and Canada, announced the appointment of Richard R. DeLuca Jr. as executive vice president and president, Merck Animal Health, effective September 15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck’s president and chief executive ...
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
02-08-2011
MorphoSys AG announced that its research and diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck & Co., Inc. to include the use of MorphoSys's HuCAL GOLD technology in the field of vaccines. Under the terms of the agreement, Merck is granted access to ...
Dieter Lütticken Award Granted to Hans-Peter Ottiger for Alternative Purity Test for Avian Vaccines
01-08-2011
Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, announced that the Dieter Lütticken Award, an international annual award dedicated to alternatives in animal testing for veterinary medicines, goes this year to Dr. Hans-Peter Ottiger. He is Head Quality Control ...
Merck Animal Health (MSD Animal Health) Breaks Ground for $18 Million Vaccine Plant Expansion
22-07-2011
Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, announced that it has embarked on the expansion of a vaccine manufacturing unit at its Biosciences Center Boxmeer campus in the Netherlands. The $18 million investment will result in a doubling of the capacity of ...
Merck & Co. Announces New Name for its Animal Health Division
01-07-2011
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that effective it will begin using the new name, Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.“The name change reflects Merck's commitment to ...
Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
10-06-2011
Merck & Co., known as MSD outside the United States and Canada, and Intercell AG announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the ...
Netmeeting
